Health tech company Tempus AI files for $100M IPO
Three years after talks of an initial public offering surfaced, health tech company Tempus AI lit the fuse and is now looking to go public this year.
Source: fiercehealthcare.com
📰 Highline Sciences News
Highline Sciences News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Highline Sciences. Real-time updates on events, politics, business and more.
Analysis of the Global AI in Clinical Trials Industry, 2023 to 2035 - Product/Technology Utilization and Integration Agreements Lead the Way in Partnerships
/PRNewswire/ -- The "Global AI in Clinical Trials Market: Trends and Forecasts 2023-2035" report has been added to ResearchAndMarkets.coms offering. The...
Source: prnewswire.com
Global AI in Clinical Trials Market Overview 2023-2035: AI
Dublin, Aug. 18, 2023 (GLOBE NEWSWIRE) -- The "AI in Clinical Trials Market: Software and Service Providers - Distribution by Trial Phase, Target...
New York United States United Kingdom Memorial Sloan Kettering Cancer Center Al Iskandariyah Cancer Institute
Source: globenewswire.com
Entrada names industry veteran Angela Busà as SVP
Entrada names industry veteran Angela Busà as SVP. From PR Week
Source: prweek.com
Tempus buys oncology data company • Illinois hospitals topping Healthgrades list • First patient gets Abbott's leadless pacemaker
Crain's Health Pulse is your source for actionable, exclusive and inside news on the health care industry.
South Bend United States Palos Community Hospital Beckman Institute Czech Republic Carle Foundation Hospital
Source: chicagobusiness.com
Tempus acquires oncology research company
San Francisco-based Highline Sciences will help Tempus expand its clinical trials business.
Source: chicagobusiness.com
Tempus Buys Highline Sciences
The acquisition will allow Tempus to vertically integrate more clinical trial services into its CRO partnerships.
Source: themiddlemarket.com